Keybank National Association OH Purchases 814 Shares of Amgen Inc. (NASDAQ:AMGN)

Keybank National Association OH grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,041 shares of the medical research company's stock after buying an additional 814 shares during the period. Keybank National Association OH's holdings in Amgen were worth $48,229,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Capital Performance Advisors LLP acquired a new stake in shares of Amgen during the third quarter worth about $25,000. Centricity Wealth Management LLC acquired a new stake in shares of Amgen during the fourth quarter worth about $25,000. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen during the third quarter worth about $29,000. Synergy Investment Management LLC acquired a new stake in shares of Amgen during the fourth quarter worth about $34,000. Finally, Heck Capital Advisors LLC acquired a new stake in Amgen in the 4th quarter valued at approximately $36,000. Institutional investors own 76.50% of the company's stock.

Insider Activity at Amgen

In related news, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is owned by company insiders.

Amgen Stock Performance

Shares of NASDAQ AMGN traded up $1.41 during midday trading on Tuesday, hitting $312.19. 3,819,193 shares of the company's stock traded hands, compared to its average volume of 2,546,395. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The stock has a market capitalization of $167.71 billion, a price-to-earnings ratio of 41.35, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm has a fifty day moving average of $282.76 and a 200 day moving average of $299.66.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.05%. Amgen's dividend payout ratio (DPR) is presently 126.09%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AMGN. Leerink Partners reduced their target price on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. William Blair reissued an "outperform" rating on shares of Amgen in a report on Tuesday, November 12th. Piper Sandler Companies reaffirmed an "overweight" rating and issued a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Redburn Partners lowered their target price on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Finally, Bank of America upped their target price on Amgen from $256.00 to $275.00 and gave the stock an "underperform" rating in a report on Thursday, February 6th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $314.09.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.